FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2167750363> ?p ?o ?g. }

• W2167750363 endingPage "543" @default.
• W2167750363 startingPage "535" @default.
• W2167750363 abstract "The net benefit (i.e., benefits minus costs) of sustained-release (SR) bupropion for smoking cessation from an employer's perspective has previously been evaluated in clinical trials including frequent, in-person behavioral counseling and manufacturer recommended dosing but not in actual practice settings and lower dosing.The objective of this research was to determine the return on investment (ROI) and internal rate of return (IRR) from an employer's perspective of two dosing schedules of bupropion SR in combination with behavioral interventions of minimal intensity (tailored mailings, TM) or moderate intensity (proactive telephone calls, PTC) in an actual practice setting.An open-label, randomized trial with 1-year follow-up was conducted in a large health system (Group Health Cooperative) based in Seattle, WA. Participants included 1524 adult smokers interested in quitting smoking. Participants were randomly assigned to receive 150 mg of bupropion SR daily and PTC (n=382), 150 mg of bupropion SR daily and TM (n=381), 300 mg of bupropion SR daily and PTC (n=383) or 300 mg of bupropion SR daily and TM (n=378). Sufficient medications for 8 weeks of dosing were provided to patients. The primary outcome measure of the field trial was self-reported point-prevalence 7-day nonsmoking status at 12 months, and the primary outcome measures of the economic analysis were employer net benefit, employer ROI, and the ROI-associated IRR using 2002 dollars.Using net benefit, the 300-mg/PTC and the 150-mg/PTC treatments were approximately equally preferred. Using ROI or IRR, both the 150-mg/TM and 150-mg/PTC treatments were about equally preferred, with IRR values of 31.7% and 31.4%, respectively. Under a pessimistic scenario regarding effectiveness and costs, 150 mg/PTC became more cost-effective than 150 mg/TM, and employer IRR for 150 mg/PTC was 13%. Under an optimistic scenario IRR exceeded 45% for all treatments.These results suggest that employers can receive competitive returns on investment from sponsoring smoking cessation programs, that 150 mg of bupropion doses yield better returns than 300-mg doses, and that PTC treatments should be preferred to TM if smoking cessation rates in the targeted employee population are lower than those in the study population." @default.
• W2167750363 created "2016-06-24" @default.
• W2167750363 creator A5016715109 @default.
• W2167750363 creator A5023155537 @default.
• W2167750363 creator A5028766106 @default.
• W2167750363 creator A5038407745 @default.
• W2167750363 creator A5061977369 @default.
• W2167750363 creator A5066793717 @default.
• W2167750363 creator A5077098928 @default.
• W2167750363 creator A5079827173 @default.
• W2167750363 date "2004-09-01" @default.
• W2167750363 modified "2023-10-13" @default.
• W2167750363 title "Return on Investment of Different Combinations of Bupropion SR Dose and Behavioral Treatment for Smoking Cessation in a Health Care Setting: An Employer's Perspective" @default.
• W2167750363 cites W1569162948 @default.
• W2167750363 cites W1988429930 @default.
• W2167750363 cites W2015027944 @default.
• W2167750363 cites W2018889637 @default.
• W2167750363 cites W2022776069 @default.
• W2167750363 cites W2027180925 @default.
• W2167750363 cites W2037405140 @default.
• W2167750363 cites W2045646685 @default.
• W2167750363 cites W2052144884 @default.
• W2167750363 cites W2062399317 @default.
• W2167750363 cites W2065488103 @default.
• W2167750363 cites W2073891038 @default.
• W2167750363 cites W2075847995 @default.
• W2167750363 cites W2085191348 @default.
• W2167750363 cites W2087289747 @default.
• W2167750363 cites W2101081697 @default.
• W2167750363 cites W2117593241 @default.
• W2167750363 cites W2133374870 @default.
• W2167750363 cites W2144943652 @default.
• W2167750363 cites W2163231665 @default.
• W2167750363 cites W2203026530 @default.
• W2167750363 cites W2228339316 @default.
• W2167750363 cites W2312609348 @default.
• W2167750363 cites W2317321545 @default.
• W2167750363 cites W2407381503 @default.
• W2167750363 cites W3006035094 @default.
• W2167750363 cites W4292234285 @default.
• W2167750363 cites W4301165978 @default.
• W2167750363 cites W4362206873 @default.
• W2167750363 cites W57822876 @default.
• W2167750363 cites W2185011055 @default.
• W2167750363 doi "https://doi.org/10.1111/j.1524-4733.2004.75005.x" @default.
• W2167750363 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/15367249" @default.
• W2167750363 hasPublicationYear "2004" @default.
• W2167750363 type Work @default.
• W2167750363 sameAs 2167750363 @default.
• W2167750363 citedByCount "31" @default.
• W2167750363 countsByYear W21677503632012 @default.
• W2167750363 countsByYear W21677503632013 @default.
• W2167750363 countsByYear W21677503632014 @default.
• W2167750363 countsByYear W21677503632016 @default.
• W2167750363 countsByYear W21677503632017 @default.
• W2167750363 countsByYear W21677503632020 @default.
• W2167750363 countsByYear W21677503632021 @default.
• W2167750363 countsByYear W21677503632022 @default.
• W2167750363 crossrefType "journal-article" @default.
• W2167750363 hasAuthorship W2167750363A5016715109 @default.
• W2167750363 hasAuthorship W2167750363A5023155537 @default.
• W2167750363 hasAuthorship W2167750363A5028766106 @default.
• W2167750363 hasAuthorship W2167750363A5038407745 @default.
• W2167750363 hasAuthorship W2167750363A5061977369 @default.
• W2167750363 hasAuthorship W2167750363A5066793717 @default.
• W2167750363 hasAuthorship W2167750363A5077098928 @default.
• W2167750363 hasAuthorship W2167750363A5079827173 @default.
• W2167750363 hasBestOaLocation W21677503631 @default.
• W2167750363 hasConcept C126322002 @default.
• W2167750363 hasConcept C142724271 @default.
• W2167750363 hasConcept C144133560 @default.
• W2167750363 hasConcept C162853370 @default.
• W2167750363 hasConcept C168563851 @default.
• W2167750363 hasConcept C1862650 @default.
• W2167750363 hasConcept C2777288759 @default.
• W2167750363 hasConcept C2777843972 @default.
• W2167750363 hasConcept C2779908668 @default.
• W2167750363 hasConcept C71924100 @default.
• W2167750363 hasConcept C79736992 @default.
• W2167750363 hasConceptScore W2167750363C126322002 @default.
• W2167750363 hasConceptScore W2167750363C142724271 @default.
• W2167750363 hasConceptScore W2167750363C144133560 @default.
• W2167750363 hasConceptScore W2167750363C162853370 @default.
• W2167750363 hasConceptScore W2167750363C168563851 @default.
• W2167750363 hasConceptScore W2167750363C1862650 @default.
• W2167750363 hasConceptScore W2167750363C2777288759 @default.
• W2167750363 hasConceptScore W2167750363C2777843972 @default.
• W2167750363 hasConceptScore W2167750363C2779908668 @default.
• W2167750363 hasConceptScore W2167750363C71924100 @default.
• W2167750363 hasConceptScore W2167750363C79736992 @default.
• W2167750363 hasIssue "5" @default.
• W2167750363 hasLocation W21677503631 @default.
• W2167750363 hasLocation W21677503632 @default.
• W2167750363 hasOpenAccess W2167750363 @default.
• W2167750363 hasPrimaryLocation W21677503631 @default.
• W2167750363 hasRelatedWork W1524509253 @default.
• W2167750363 hasRelatedWork W1572203712 @default.
• W2167750363 hasRelatedWork W1966046147 @default.

• next